skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site


Galectin-3: clinical utility and prognostic value in patients with heart failure


(3882) Total Article Views

Authors: Kramer F

Published Date February 2013 Volume 2013:4 Pages 13 - 22

Frank Kramer

Clinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, Germany

Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.

Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification

Post to:
Cannotea Citeulike Facebook LinkedIn Twitter

Readers of this article also read: